drugset / Trial / NCT04814004
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Phase 1
Unknown
20 enrolled
Kai Lin Xu; Jun Nian Zheng
Affiliated Hospital of Jiangsu University · collabFirst Affiliated Hospital of Zhejiang University · collabHuai'an First People's Hospital · collabNantong University · collabNorth Jiangsu People's Hospital · collabThe First People's Hospital of Changzhou · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.
Timeline
- Start
- 2021-03-19
- Primary completion
- 2023-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hCD19.IL15.CAR-iNKT | Unknown | — | Intravenous |